GPT and hepatocellular carcinoma: Additionally, a study [114] conducted in South Korea found that the cumulative incidence of HCC in untreated immune-tolerant patients (ALT < 30 U/L for males, ALT < 19 U/L for females) was 12.7%, which was significantly higher than that in treated patients in immune reactivation phase (6.1%, ALT > 80 U/L).